Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Aglatimagene besadenovec’s likelihood of approval (LoA) and phase transition for High-Grade Glioma took place on 22 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Aglatimagene besadenovec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Aglatimagene besadenovec overview

aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma. malignant glioma, pediatric malignant glioma including glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma and recurrent ependymomas, advanced non-metastatic pancreatic adenocarcinoma and prostate cancer. The therapeutic drug candidate consists of (AdV-tk) adenovirus-mediated expression of herpes simplex virus thymidine kinase and valacyclovir in combination with radiation therapy. AdV-tk is administered as intra-tumoral injection and valacyclovir is administered orally. It is developed based on the gene mediated cytotoxic immunotherapy (GMCI) technology.

Candel Therapeutics overview

Candel Therapeutics, formerly Advantagene, is a biopharmaceutical company. It manufactures, develops, and tests cancer immunotherapy drugs and gene-based biologics. Candel Therapeutics offers CAN-2409 and CAN-3110, for the treatment of a broad range of solid tumor indications. It is focused on developing oncolytic viral immunotherapies for the treatment of cancer patients. The company’s oncolytic viral immunotherapy platforms use genetically engineered viruses to induce immunogenic death through viral-mediated cytotoxicity in cancer cells. Its products, CAN-3110 and CAN-2409 are used in the treatment of prostate cancer, brain cancer, pancreatic cancer, lung cancer, malignant pleural effusion, and mesothelioma. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.

Quick View Aglatimagene besadenovec LOA Data

Report Segments
  • Innovator
Drug Name
  • Aglatimagene besadenovec
Administration Pathway
  • Intratumor
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.